PacBio, a leading provider of high-quality sequencing solutions, announced today the appointment of Haorui Gene as an official distributor in China. This strategic partnership aims to expand access to PacBio's HiFi long-read sequencing technology across Chinese clinical and research settings, with a particular focus on transfusion medicine and hematology applications.
The distribution arrangement formalizes an existing relationship between the two companies and represents a significant step toward establishing PacBio's HiFi sequencing as the method of choice in blood genomics throughout China, one of the world's fastest-growing clinical genomics markets.
Strategic Expansion in Transfusion Medicine
Founded in 2020, Haorui Gene has quickly established itself as a key player in blood typing genomics. The company has already deployed seven Sequel II and three Revio systems across China to support large-scale efforts in HLA typing, blood group genotyping, and rare blood type discovery.
"This arrangement formalizes a strong foundation and supports our broader goal to make accurate, long-read sequencing standard practice in clinical genomics," said Christian Henry, President and Chief Executive Officer of PacBio. "Haorui Gene has built deep expertise in one of the most genomically complex areas of medicine."
Under the terms of the agreement, Haorui Gene will distribute PacBio's Vega platform throughout China. This technology, combined with Haorui Gene's existing product portfolio, will provide end-to-end support for clinical laboratories, blood centers, and genomics institutions seeking to build more comprehensive blood group profiles.
Clinical Impact and Technical Advantages
The partnership addresses critical needs in transfusion medicine, where precision and completeness of genomic data directly impact patient outcomes. PacBio's HiFi technology offers exceptional accuracy across full-length genes, structural variants, and highly polymorphic regions that are essential for transfusion safety and donor matching.
Haorui Gene's implementation of PacBio technology has already yielded significant clinical advances. In 2022, the company introduced a HiFi-based HLA typing product, followed by comprehensive blood group genotyping panels in 2023. Last year, Haorui expanded its collaborations with major blood centers to deepen national research efforts in rare blood classification and erythrocyte antigen mapping.
"Together with PacBio, we are committed to delivering high-standard clinical diagnostics and expanding the frontiers of long-read sequencing in healthcare," said Wang Bo, General Manager of Haorui Gene. "This collaboration reinforces our shared goal of enabling transformative discoveries in hematology and beyond."
Scientific Validation and Market Momentum
The clinical and scientific value of this partnership is supported by Haorui Gene's track record of over 20 peer-reviewed publications and widespread adoption in Chinese blood centers. Their work demonstrates the growing momentum behind long-read sequencing as a foundational tool for the future of personalized transfusion medicine.
PacBio's HiFi technology addresses limitations of traditional sequencing methods by providing high-resolution, allele-level insights into complex genomic regions that are often missed by conventional approaches. This capability is particularly valuable in transfusion medicine, where detailed genetic information can prevent adverse transfusion reactions and improve patient outcomes.
Future Implications
This expanded partnership reflects a shared commitment to making high-precision sequencing more widely available for healthcare applications that depend on accuracy at scale. As the Chinese clinical genomics market continues to grow, the collaboration between PacBio and Haorui Gene positions both companies to play a significant role in advancing precision medicine through genomic technologies.
The distribution agreement focuses initially on transfusion medicine and hematology but creates infrastructure for potential expansion into other clinical areas where long-read sequencing offers advantages over traditional genomic approaches.
For both companies, the partnership represents an important step in bridging the gap between advanced genomic technologies and routine clinical practice, potentially transforming how genetic information is used in patient care across China's vast healthcare system.
